Global Tardive Dyskinesia Treatment Market 2019-2023

Global Tardive Dyskinesia Treatment Market 2019-2023

About Tardive Dyskinesia

Tardive dyskinesia is the involuntary movement of face and body as a side effect of using antipsychotic drugs for the treatment of mental disorders such as schizophrenia, bipolar disorder, and other brain conditions.

Technavio’s analysts forecast the Global Tardive Dyskinesia Treatment Market to grow at a CAGR of 4.44% during the period 2019-2023.

Covered in this report

The report covers the present scenario and the growth prospects of the tardive dyskinesia treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of tardive dyskinesia across the globe.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, tardive dyskinesia treatment market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• F. Hoffmann-La Roche
• Merck
• Neurocrine Biosciences
• Novartis
• Teva Pharmaceutical

Market driver

Increasing use of antipsychotic drugs across the globe

For a full, detailed list, view our report

Market challenge

• Lack of awareness
• For a full, detailed list, view our report

Market trend

• Increasing R&D on VMAT2 inhibitors
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2023 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?